埃兹蛋白和肺癌肿瘤抑制物1在肝癌组织中的表达及其与预后的关系

Expression of Ezrin and tumor suppressor in lung cancer 1 and significance in primary liver carcinoma

目的 探讨埃兹蛋白（Ezrin）和肺癌肿瘤抑制物1（TSLC1）在原发性肝癌（PLC）组织中的表达及两者与PLC临床病理特征和预后之间的关系.方法 采用免疫组织化学法检测66例PLC、30例肝硬化和15例正常肝组织中Ezrin和TSLC1表达水平.结果 Ezrin蛋白在PLC、肝硬化和正常肝组织中的表达率分别为81.82％ （54/66） 、60.00％ （18/30）和26.67％ （4/15）,两两比较差异有统计学意义（P＜0.01）,TSLC1蛋白在PLC、肝硬化和正常肝组织中的表达率分别为37.88％（25/66） 、63.33％（19/30）和93.33％（14/15）,两两比较差异有统计学意义（P＜0.05）;Ezrin表达水平与PLC肿瘤大小、血管浸润、TNM分期有关（P＜0.05）,TSLC1表达水平与PLC血管浸润、TNM分期有关（P＜0.05）.结论 Ezrin和TSLC1可作为评估PLC患者的不良预后指标.

Objective To investigate the expression of Ezrin and tumor suppressor in lung cancer 1 （TSLC1） in primary liver carcinoma （PLC）,and their relation to the clinicopathological features and the prognostic value.Methods Immunohistochemical method was used to detect the expression of Ezrin protein and TSLC1 protein in 66 cases of PLC tissues,30 cases of cirrhosis tissues and 15 cases of normal liver tissues.Results The expression rate of Ezrin in PLC tissues,cirrhosis tissues and normal liver tissues was 81.82% （54/66）,60.00% （18/30） and 26.67% （4/15） respectively （P 〈 0.05）.The expression rate of TSLC1 in PLC tissues,cirrhosis tissues and normal liver tissues was 37.88% （25/66）,63.33%（19/30） and 93.33% （14/15） respectively （P 〈 0.05）.The expression of Ezrin was related to PLC tumor size,vascular invasion and TNM stage （P 〈 0.05）,and there was a close relation between the expression of TSLC1 with vascular invasion and and TNM stage in PLC （P 〈 0.05）.Conclusion Ezrin and TSLC1 may be used as poor prognosis markers of PLC patients.